Global initiative to scale advanced therapeutic treatments to accelerate patient access worldwide. TUCSON, Ariz. and AMSTERDAM, March 26, 2026 /PRNewswire/ -- Critical Path Institute® (C-Path) today ...

Critical Path Institute’s Translational Therapeutics Accelerator has invested in the development of QED-203 for advanced and therapy-resistant prostate cancer. Based on research at the University of ...

TUCSON, Ariz., November 19, 2024 — Critical Path Institute® (C-Path) today announced that its Translational Therapeutics Accelerator (TRxA) program, in partnership with The Leona M. and Harry B.

Critical Path Institute (C-Path) is pleased to announce the release of a new peer-reviewed publication, titled "Transforming Drug Development for Neurological Disorders: Proceedings from a ...

TUCSON, Ariz., and AMSTERDAM March 26, 2026 — Critical Path Institute® (C-Path) today announced the launch of One to Millions, a global, multi-stakeholder public-private initiative to enable scalable ...

To help close this gap, One to Millions advances the U.S. Food and Drug Administration (FDA) Plausible Mechanism Framework and Rare Disease Evidence Principles by leveraging C-Path's centralized, ...